A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

NCT03227861 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1

Interventions

DRUG: DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC

Sponsor

Janssen Scientific Affairs, LLC